CrystalLeeMackallMD

Pediatric Hematology & Oncology • Palo Alto, CA

Physician

Join to view full profile

Dr. Mackall is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Mackall's full profile

Already have an account?

Office
725 Welch Rd
Palo Alto, CA 94304
Phone+1 650-497-8953

Fax+1 650-497-8959
Is this information wrong?

Education & Training

National Capital ConsortiumFellowship, Pediatric Hematology/Oncology, 1989 - 1992
Akron General Medical Center/NEOMEDResidency, Internal Medicine, 1984 - 1988
Northeast Ohio Medical UniversityClass of 1984

Certifications & Licensure

CA State Medical License 2016 - 2025
OH State Medical License 1984 - 2018
MD State Medical License 1994 - 2017
DC State Medical License 1994 - 1998
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

Whos Who in Medicine and Healthcare Marquis Whos Who
Elected Member The American Society for Clinical Investigation, 2005

Clinical Trials

A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas Start of enrollment: 1996 Dec 23
Completed
Phase 2
A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas Start of enrollment: 1996 Dec 01
Completed
Phase 2
Evaluation, Treatment, and Natural History of Children and Young Adults With Cancer or Rare Diseases Start of enrollment: 1998 Mar 19
Completed
Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy Start of enrollment: 2000 Mar 03
Completed
Phase 1
Surveillance of Fungal Infections in Bone Marrow/Stem Cell and Organ Transplant Recipients Start of enrollment: 2001 Apr 09
Completed
Eligibility Screening for a NCI Pediatric Oncology Branch Research Study Start of enrollment: 2001 Sep 24
Completed
Prognostic Value of a Positive RT-PCR Test in Patients With Ewing Sarcoma Start of enrollment: 2004 Mar 12
Completed
HGS-ETR2 to Treat Children With Solid Tumors Start of enrollment: 2006 Dec 04
Terminated
Phase 1
Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma Start of enrollment: 2007 Jun 02
Completed
Phase 1, Phase 2
Enrollment on the Childhood Cancer Research Network (CCRN) of the Children s Oncology Group Start of enrollment: 2010 Apr 30
Terminated
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma Start of enrollment: 2012 Sep 27
Completed
Phase 1
Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer Start of enrollment: 2007 Oct 01
Completed
Phase 1
A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors Start of enrollment: 2014 Feb 28
Completed
Phase 1
Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors Start of enrollment: 2016 Dec 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

FOXO1 is a master regulator of memory programming in CAR T cells.
Alexander E Doan, Katherine P Mueller, Andy Y Chen, Geoffrey T Rouin, Yingshi Chen, Bence Daniel, John Lattin, Martina Markovska, Brett Mozarsky, Jose Arias-Umana, Rob...> ;Nature. 2024 Apr 10
Directed evolution of genetically encoded LYTACs for cell-mediated delivery.
Jonathan Lee Yang, Sean A Yamada-Hunter, Louai Labanieh, Elena Sotillo, Joleen S Cheah, David S Roberts, Carolyn R Bertozzi, Alice Y Ting, Crystal L Mackall> ;Proceedings of the National Academy of Sciences of the United States of America. 2024 Mar 26
CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results.
Rezvani, A. R., Liora M Schultz, Nikeshan Jeyakumar, Anne Marijn Kramer, Bita Sahaf, Hrishi Srinagesh, Parveen Shiraz, Neha Agarwal, Mark Hamilton, Courtney Erickson, ...> ;Leukemia. 2024 Mar 15
1 citations
A versatile CRISPR-Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells.
Victor Tieu, Elena Sotillo, Jeremy R Bjelajac, Crystal Chen, Meena Malipatlolla, Justin A Guerrero, Peng Xu, Patrick J Quinn, Chris Fisher, Dorota Klysz, Crystal L Mac...> ;Cell. 2024 Feb 29
2 citations
Inosine induces stemness features in CAR-T cells and enhances potency.
Klysz, D., Fowler, C., Malipatlolla, M., Stuani, L., Freitas, K., Chen, Y., Meier, S., Daniel, B., Sandor, K., Xu, P., Huang, J., Labanieh, L., Keerthi, V., Leruste, A...> ;Cancer Cell. 2024 Feb 12
3 citations
Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy.
Sabina Kaczanowska, Tara Murty, Ahmad Alimadadi, Cristina F Contreras, Caroline Duault, Priyanka B Subrahmanyam, Warren Reynolds, Norma A Gutierrez, Reema Baskar, Cath...> ;Cancer Cell. 2024 Jan 8
1 citations
Directed Evolution of Genetically Encoded LYTACs for Cell-Mediated Delivery.
Jonathan Lee Yang, Sean A Yamada-Hunter, Louai Labanieh, Elena Sotillo, Joleen S Cheah, David S Roberts, Alice Y Ting, Carolyn R Bertozzi, Crystal L Mackall> ;Biorxiv. 2023 Nov 15
1 citations
FOXO1 is a master regulator of CAR T memory programming.
Alexander Doan, Katherine P Mueller, Andy Chen, Geoffrey T Rouin, Bence Daniel, John Lattin, Yingshi Chen, Brett Mozarsky, Martina Markovska, Jose Arias-Umana, Robert ...> ;Research Square. 2023 Nov 7
Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-...
Valentin Barsan, Yimei Li, Snehit Prabhu, Christina Baggott, Khanh Nguyen, Holly Pacenta, Christine L Phillips, Jenna Rossoff, Heather Stefanski, Julie-An Talano, Amy ...> ;Eclinicalmedicine. 2023 Nov 1
5 citations
Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing.
Hyatt Balke-Want, Vimal Keerthi, Nikolaos Gkitsas, Andrew G Mancini, Gavin L Kurgan, Carley Fowler, Peng Xu, Xikun Liu, Kyle Asano, Sunny Patel, Christopher J Fisher, ...> ;Molecular Cancer. 2023 Jun 26
5 citations
Author Correction: CAR immune cells: design principles, resistance and the next generation.
Louai Labanieh, Crystal L Mackall> ;Nature. 2023 Jul 1
1 citations
The future of CAR T-cell therapy for B-cell acute lymphoblastic leukemia in pediatrics and adolescents.
Liora Schultz, Crystal L Mackall> ;Expert Opinion on Biological Therapy. 2023 Jun 23
5 citations
Inosine Induces Stemness Features in CAR T cells and Enhances Potency.
Dorota D Klysz, Carley Fowler, Meena Malipatlolla, Lucille Stuani, Katherine A Freitas, Stefanie Meier, Bence Daniel, Katalin Sandor, Peng Xu, Jing Huang, Louai Labani...> ;Biorxiv. 2023 Apr 25
16 citations
Tumor inflammation-associated neurotoxicity.
Jasia Mahdi, Jorg Dietrich, Karin Straathof, Claire Roddie, Brian J Scott, Tom Belle Davidson, Laura M Prolo, Tracy T Batchelor, Cynthia J Campen, Kara L Davis, Julian...> ;Nature Medicine. 2023 Apr 1
1 citations
HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL.
Kevin O McNerney, Stephanie J Si Lim, Kyle Ishikawa, Alexandra Dreyzin, Anant Vatsayan, John J Chen, Christina Baggott, Snehit Prabhu, Holly L Pacenta, Christine Phili...> ;Blood Advances. 2023 Jun 27
20 citations
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium.
Heather E Stefanski, Anne Eaton, Christina Baggott, Jenna Rossoff, Michael R Verneris, Snehit Prabhu, Holly L Pacenta, Christine L Phillips, Julie-An Talano, Amy Mosko...> ;Blood Advances. 2023 Feb 28
79 citations
CAR immune cells: design principles, resistance and the next generation.
Louai Labanieh, Crystal L Mackall> ;Nature. 2023 Feb 1
22 citations
Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia.
Liora M Schultz, Anne Eaton, Christina Baggott, Jenna Rossoff, Snehit Prabhu, Amy K Keating, Christa Krupski, Holly Pacenta, Christine L Philips, Julie-An Talano, Amy ...> ;Journal of Clinical Oncology. 2023 Jan 10
31 citations
Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas.
Jin, M., Brian J Sworder, David M Kurtz, Stefan K Alig, Matthew J Frank, Navika Shukla, Andrea Garofalo, Charles W Macaulay, Mohammad Shahrokh Esfahani, Mari N Olsen, ...> ;Cancer Cell. 2023 Jan 9
8 citations
The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes.
Aiman J Faruqi, John A Ligon, Paul Borgman, Seth M Steinberg, Toni Foley, Lauren Little, Crystal L Mackall, Daniel W Lee, Terry J Fry, Haneen Shalabi, Jennifer Brudno,...> ;Blood Advances. 2022 Dec 13
11 citations
A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412.
Kara L Davis, Elizabeth Fox, Emasenyie Isikwei, Joel M Reid, Xiaowei Liu, Charles G Minard, Stephan Voss, Stacey L Berg, Brenda J Weigel, Crystal L Mackall> ;Clinical Cancer Research. 2022 Dec 1
30 citations
Enhanced T cell effector activity by targeting the Mediator kinase module.
Katherine A Freitas, Julia A Belk, Elena Sotillo, Patrick J Quinn, Maria C Ramello, Meena Malipatlolla, Bence Daniel, Katalin Sandor, Dorota Klysz, Jeremy Bjelajac, Pe...> ;Science. 2022 Nov 11
4 citations
Neurotoxicity following CD19/CD28ζ CAR T-cells in children and young adults with B-cell malignancies.
Haneen Shalabi, Staci Martin, Bonnie Yates, Pamela L Wolters, Claire Kaplan, Hannah Smith, Christopher R Sesi, Jennifer Jess, Mary Anne Toledo-Tamula, Kari Struemph, C...> ;Neuro-Oncology. 2022 Sep 1
69 citations
Post-infusion CAR Tcells identify patients resistant to CD19-CAR therapy.
Zinaida Good, Jay Y Spiegel, Bita Sahaf, Meena B Malipatlolla, Zach J Ehlinger, Sreevidya Kurra, Moksha H Desai, Warren D Reynolds, Anita Wong Lin, Panayiotis Vandris,...> ;Nature Medicine. 2022 Sep 1
20 citations
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia.
Amy Moskop, Lauren Pommert, Christina Baggott, Snehit Prabhu, Holly L Pacenta, Christine L Phillips, Jenna Rossoff, Heather E Stefanski, Julie-An Talano, Steve P Margo...> ;Blood Advances. 2022 Jul 26
Join now to see all

Journal Articles

Fludarabine and Neurotoxicity in Engineered T-cell Therapy
Elliot Norry, Crystal L Mackall, Nature
Tumor Antigen Escape from CAR T-cell Therapy
Crystal L Mackall, Robbie G Majzner, Clinical Cancer Research

Abstracts/Posters

Allogeneic Chimeric Antigen Receptor-Invariant Natural Killer T Cells Exert Both Direct and Indirect Antitumor Effects through Host CD8 T Cell Cross-Priming
Crystal L. Mackall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Identification of Dual Positive CD19+/CD3+ T Cells in an Apheresis Product Undergoing Chimeric Antigen Receptor (CAR) Transduction
Crystal L. Mackall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL)
Crystal L. Mackall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Detectable Circulating Tumor DNA 28 Days after the CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucel, Is Associated with Poor Outcomes in Patients with Diffuse Large B-...
Crystal L. Mackall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Infectious Complications Associated with CAR T-Cell Therapy
Crystal L. Mackall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy
Crystal L. Mackall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
CNS Endothelial Cell Activation Emerges as a Driver of CAR T Cell–Associated Neurotoxicity
Crystal Mackall, MD, Clinical Cancer Research, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Plenary
American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/3/2019

Press Mentions

The Race to Supercharge Cancer-Fighting T CellsJanuary 25th, 2023
Crystal Mackall: Expanding the Reach of CAR T-cell TherapyOctober 17th, 2022
To Save Children with Cancer, Doctors Turn to New WeaponsAugust 5th, 2022
Join now to see all

Grant Support

Immunobiology And Immunotherapy Of Pediatric TumorsNational Cancer Institute2011
Biology And Therapy Of LymphopeniaNational Cancer Institute2011
Clinical Program In Pediatric SarcomasNational Cancer Institute2010–2011
Immunobiology Of Pediatric TumorsNational Cancer Institute2010
Developing Immune Based TherapiesNational Cancer Institute2010
Biology Of T Cell DepletionNational Cancer Institute2010
Immunobiology Of Pediatric TumorsDivision Of Basic Sciences - Nci2009
Developing Immune Based TherapiesDivision Of Basic Sciences - Nci2009
Clinical Program In Pediatric SarcomasDivision Of Basic Sciences - Nci2009
Biology Of T Cell DepletionDivision Of Basic Sciences - Nci2009
Developing Immune Based TherapiesNational Cancer Institute2008
Clinical Program In Pediatric SarcomasNational Cancer Institute2008
Biology Of T Cell DepletionNational Cancer Institute2008
Immunobiology And Immunotherapy Of Pediatric TumorsNational Cancer Institute2007
Biology And Therapy Of T Cell DepletionNational Cancer Institute2007
Immunobiology And Immunotherapy Of Pediatric TumorsDivision Of Clinical Sciences - Nci2003–2006
Biology And Therapy Of T Cell DepletionDivision Of Clinical Sciences - Nci2003–2006
Clinical Trials Of Immune Reconstitution/Tumor VaccinatiDivision Of Clinical Sciences - Nci2001–2002
Directing T Cell Responses During Immune ReconstitutionDivision Of Clinical Sciences - Nci1999–2002
Clinical Trials Of Immune Reconstitution/Tumor Vaccination In Pediatric SarcomasDivision Of Clinical Sciences - Nci1999–2000
Directing Immune Responses During Immune ReconstitutionDivision Of Clinical Sciences - Nci1998